We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarkers Found for Metastatic Breast Tumor Cells

By LabMedica International staff writers
Posted on 23 Apr 2013
Some breast tumor circulating cells in the bloodstream are marked by a constellation of biomarkers that identify them as those destined to metastasize in the brain. More...


Sophisticated techniques have been used to test samples of circulating breast tumor cells to identify and characterize the biomarkers that are the signature of the cells destined to seed the brain with a deadly spread of cancer.

Scientists at Baylor College of Medicine (Houston, TX, USA) collected blood samples from 38 patients with metastatic or nonmetastatic breast cancer. Isolated peripheral blood mononuclear cells (PBMCs) were separated, analyzed, and sorted with the BD FACSAria II 3Laser high-speed sorting flowcytometer (Becton Dickinson; Franklin Lakes, NJ, USA). The circulating tumor cells were cultured and injected into animals. Total ribonucleic acid (RNA) from the PBMCs was amplified by real time polymerase chain reaction.

The biomarkers identified by the scientists included human epidermal growth factor receptor 2 (HER2+), epidermal growth factor receptor (EGFR), heparanase (HPSE) and Notch1, a single-pass transmembrane receptor. Together, these four proteins, previously known to be associated with cancer metastasis, spell out the signature of circulating tumors cells that travel to the brain. The scientists did not find evidence of the epithelial cell adhesion molecule (EpCAM). The study not only identifies a novel signature of circulating tumor cells, it shows the limitations of currently approved platforms used to identify cancer in this way. Analyzing such cells can help scientist understand how the disease spreads, which may be an initial step in developing new methods of treating metastatic disease.

Dario Marchetti, PhD, professor of pathology and lead author said, "We don't claim that these biomarkers are the only important ones. We hope to find novel markers in brain metastasis that will make diagnosis and monitoring even more targeted." The investigators are also trying to find ways to link these circulating tumor cells back to the signature of the original or primary tumor. The study was published on April 10, 2013, in the journal Science Translational Medicine.

Related Links:

Baylor College of Medicine
Becton Dickinson




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.